The review found no eligible studies for this question.
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes regression of endometrial hyperplasia (with or without atypia) to… compared with levonorgestrel intrauterine system (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes hysterectomy rate compared with levonorgestrel intrauterine system (very low certainty).
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes abnormal uterine bleeding compared with levonorgestrel intrauterine system (very low certainty).
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes adverse effects during treatment ‐ all effects compared with levonorgestrel intrauterine system (very low certainty).
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes adverse effects during treatment ‐ nausea compared with levonorgestrel intrauterine system (very low certainty).
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes adverse effects during treatment ‐ heaviness in lower abdomen compared with levonorgestrel intrauterine system (very low certainty).
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes adverse effects during treatment ‐ pain in abdomen compared with levonorgestrel intrauterine system (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether summary of findings of metformin monotherapy for adults with type 2… changes all‐cause mortality compared with thiazolidinediones (very low certainty).
It is very uncertain whether summary of findings of metformin monotherapy for adults with type 2… changes serious adverse events (SAE) compared with thiazolidinediones (very low certainty).
The review found no eligible studies for this question.